2026-05-06
Neuropsychiatric systemic lupus erythematosus – toward new treatments ?
Rhumatology
By Ana Espino | Published on May 6, 2026 | 4 min read
Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by the production of autoantibodies and systemic inflammation that can affect multiple organs, including the central nervous system. When the latter is involved, the condition is referred to as neuropsychiatric lupus (NPSLE), a common and particularly disabling form that may affect up to 80% of patients.
NPSLE encompasses a wide range of manifestations, from cognitive impairment, fatigue, mood disorders, or psychosis, to more focal conditions such as stroke or seizures. While some forms can be managed symptomatically, diffuse central nervous system involvement remains difficult to treat and represents a major unmet medical need.
The underlying mechanisms are complex and include systemic inflammation, the production of brain-targeting autoantibodies, and disruption of the blood–brain barrier, allowing these antibodies to enter brain tissue. Despite therapeutic advances in SLE, few treatments specifically target these manifestations, partly because NPSLE patients are often excluded from clinical trials.
In this context, this review, recently published in Current Opinion in Rheumatology, aims to provide an overview of current and emerging treatments for NPSLE, highlighting new therapeutic strategies derived from experimental models and clinical data.
Current management relies primarily on immunosuppression. In the acute phase, high-dose glucocorticoids, often combined with cyclophosphamide, are the standard treatment. Other options such as rituximab, intravenous immunoglobulins, or plasma exchange may be used in refractory cases.
However, these treatments remain non-specific, and their effectiveness in diffuse NPSLE is limited. Current and emerging therapeutic strategies target several mechanisms: autoantibodies, systemic inflammation, the blood–brain barrier, and neuroinflammation.
Emerging approaches include:
• Targeting B lymphocytes and autoantibodies, with therapies such as CAR T cells or BTK inhibitors
• Reducing systemic inflammation, notably through JAK, TYK2 inhibitors, or anti-interferon antibodies
• Direct neuroprotection, using molecules capable of limiting microglial activation
Some innovative strategies also aim to directly block pathogenic autoantibodies or prevent their interaction with neuronal targets.
A key element of the disease’s pathophysiology is the integrity of the blood–brain barrier. Its increased permeability in lupus patients facilitates the passage of neurotoxic antibodies into the brain. Factors such as the gut microbiota or stress may modulate this barrier, opening the way to novel therapeutic approaches.
Finally, recent studies highlight the central role of microglia in sustaining brain inflammation. Angiotensin-converting enzyme (ACE) inhibitors capable of crossing the blood–brain barrier appear to be a promising avenue for limiting these neuroinflammatory processes.
Neuropsychiatric lupus remains a complex, poorly understood condition that is difficult to treat, particularly in its diffuse forms. This review highlights a major shift in the therapeutic paradigm, moving from broad immunosuppression toward more targeted strategies.
New approaches—whether targeting B cells, inhibiting cytokines, or modulating neuroinflammation—offer promising prospects for improving patient management.
Beyond these advances, this work underscores the importance of better including NPSLE patients in clinical trials to properly assess the real-world effectiveness of these treatments. The next steps will be to validate these strategies in dedicated clinical trials, deepen understanding of the underlying mechanisms—particularly at the level of the blood–brain barrier and microglia—and develop truly personalized treatments at the intersection of immunology and neuroscience.
Read next : Lupus under control?
About the author – Ana Espino
PhD in Immunology, specialized in Virology
As a scientific writer, Ana is passionate about bridging the gap between research and real-world impact. With expertise in immunology, virology, oncology, and clinical studies, she makes complex science clear and accessible. Her mission: to accelerate knowledge sharing and empower evidence-based decisions
Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by the production of autoantibodies and systemic inflammation that can affect multiple organs, including the central nervous system. When the latter is involved, the condition is referred to as neuropsychiatric lupus (NPSLE), a common and particularly disabling form that may affect up to 80% of patients.
NPSLE encompasses a wide range of manifestations, from cognitive impairment, fatigue, mood disorders, or psychosis, to more focal conditions such as stroke or seizures. While some forms can be managed symptomatically, diffuse central nervous system involvement remains difficult to treat and represents a major unmet medical need.
The underlying mechanisms are complex and include systemic inflammation, the production of brain-targeting autoantibodies, and disruption of the blood–brain barrier, allowing these antibodies to enter brain tissue. Despite therapeutic advances in SLE, few treatments specifically target these manifestations, partly because NPSLE patients are often excluded from clinical trials.
In this context, this review, recently published in Current Opinion in Rheumatology, aims to provide an overview of current and emerging treatments for NPSLE, highlighting new therapeutic strategies derived from experimental models and clinical data.
What strategies to treat the brain ?
Current management relies primarily on immunosuppression. In the acute phase, high-dose glucocorticoids, often combined with cyclophosphamide, are the standard treatment. Other options such as rituximab, intravenous immunoglobulins, or plasma exchange may be used in refractory cases.
However, these treatments remain non-specific, and their effectiveness in diffuse NPSLE is limited. Current and emerging therapeutic strategies target several mechanisms: autoantibodies, systemic inflammation, the blood–brain barrier, and neuroinflammation.
Emerging approaches include:
• Targeting B lymphocytes and autoantibodies, with therapies such as CAR T cells or BTK inhibitors
• Reducing systemic inflammation, notably through JAK, TYK2 inhibitors, or anti-interferon antibodies
• Direct neuroprotection, using molecules capable of limiting microglial activation
Some innovative strategies also aim to directly block pathogenic autoantibodies or prevent their interaction with neuronal targets.
A key element of the disease’s pathophysiology is the integrity of the blood–brain barrier. Its increased permeability in lupus patients facilitates the passage of neurotoxic antibodies into the brain. Factors such as the gut microbiota or stress may modulate this barrier, opening the way to novel therapeutic approaches.
Finally, recent studies highlight the central role of microglia in sustaining brain inflammation. Angiotensin-converting enzyme (ACE) inhibitors capable of crossing the blood–brain barrier appear to be a promising avenue for limiting these neuroinflammatory processes.
Toward targeted treatments for NPSLE ?
Neuropsychiatric lupus remains a complex, poorly understood condition that is difficult to treat, particularly in its diffuse forms. This review highlights a major shift in the therapeutic paradigm, moving from broad immunosuppression toward more targeted strategies.
New approaches—whether targeting B cells, inhibiting cytokines, or modulating neuroinflammation—offer promising prospects for improving patient management.
Beyond these advances, this work underscores the importance of better including NPSLE patients in clinical trials to properly assess the real-world effectiveness of these treatments. The next steps will be to validate these strategies in dedicated clinical trials, deepen understanding of the underlying mechanisms—particularly at the level of the blood–brain barrier and microglia—and develop truly personalized treatments at the intersection of immunology and neuroscience.
Read next : Lupus under control?
About the author – Ana Espino
PhD in Immunology, specialized in Virology
As a scientific writer, Ana is passionate about bridging the gap between research and real-world impact. With expertise in immunology, virology, oncology, and clinical studies, she makes complex science clear and accessible. Her mission: to accelerate knowledge sharing and empower evidence-based decisions
Last press reviews
Neuropsychiatric systemic lupus erythematosus – toward new treatments ?
By Ana Espino | Published on May 6, 2026 | 4 min read<br><br><br>Sys...
Cancer: AI-measured “facial aging” emerges as a new prognostic biomarker
By Elodie Vaz | Published on May 6, 2026 | 4 min read<br><br><br>
Asthma: men and women, the same disease?
By Ana Espino | Published on May 5, 2026 | 4 min read